CORDIS
EU research results

CORDIS

English EN

A novel generation of skin substitutes to clinically treat a broad spectrum of severe skin defects

Project information

Grant agreement ID: 279024

Status

Closed project

  • Start date

    1 October 2011

  • End date

    30 September 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 875 214,54

  • EU contribution

    € 5 996 018

Coordinated by:

UNIVERSITAT ZURICH

Switzerland

Objective

Large full-thickness skin defects resulting from burns, soft tissue trauma, congenital giant nevi, tumour resection, and disease leading to skin necrosis, represent a significant and common clinical problem worldwide. This problem is far from being solved. The main challenge encountered is that most autologous skin grafting techniques are based on transplanting split-thickness skin (the today’s gold standard). Split-thickness skin contains all of the epidermis, but only remnants of the dermis. This lack of dermal tissue, frequently leads to significant scarring. Consequently, a true dermal substitute is required, which instantly exerts the cell-instructive properties of a neo-dermis. The partners of EuroSkinGraft can now offer 2 dermal substitutes, Novomaix and denovoDerm, plus the dermo-epidermal skin substitute denovoSkin. The development of all 3 substitutes was significantly supported by the FP6-program (EuroSTEC). The envisaged clinical studies are aiming strictly at a one-step surgical procedure (instead of the common two-step procedure, using Integra Artificial Skin).This is to be reached with the following protocol:
Clinical application of Novomaix
1. Experimental arm 1: split-thickness skin on Novomaix applied on full-thickness wounds
2. Reference arm 1: split-thickness skin applied directly on the wound bed
Clinical application of denovoDerm
1. Experimental arm 1: split-thickness skin on denovoDerm applied on full-thickness wounds
2. Reference arm 1: split-thickness skin applied directly on the wound bed
Clinical application of denovoSkin
1. Experimental arm 1: denovoSkin applied on full-thickness wounds
2. Reference arm 1: split-thickness skin applied directly on the wound bed
The strength of this project lies in: the high degree to which real regenerative medicine is translated into the clinic, the innovative and highly functional character of the 3 products to be tested, the central contribution of the 3 SMEs, and the excellence of the 3 clinics.

Coordinator

UNIVERSITAT ZURICH

Address

Ramistrasse 71
8006 ZÜRich

Switzerland

Activity type

Other

EU Contribution

€ 3 020 144,34

Administrative Contact

Ernst Reichmann (Dr.)

Participants (9)

VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG

Netherlands

VEREIN FUER BERUFSGENOSSENSCHAFTLICHE HEILBEHANDLUNG BERLIN EV

Germany

EU Contribution

€ 726 060

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 425 580

MATRICEL GMBH

Germany

EU Contribution

€ 302 520

THE MEDICAL DEVICE CO LTD

United Kingdom

EU Contribution

€ 402 930

GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Germany

EU Contribution

€ 209 919,76

STICHTING VUMC

Netherlands

EU Contribution

€ 874 852

ARTTIC

France

EU Contribution

€ 34 011,90

STICHTING VU

Netherlands

Project information

Grant agreement ID: 279024

Status

Closed project

  • Start date

    1 October 2011

  • End date

    30 September 2016

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 875 214,54

  • EU contribution

    € 5 996 018

Coordinated by:

UNIVERSITAT ZURICH

Switzerland

This project is featured in...